Vaccination provides many health and economic benefits to individuals and society, and public support for immunization programs is generally high. However, the benefits of vaccines are often not fully valued when public discussions on vaccine safety, quality or efficacy arise, and the spread of misinformation via the internet and other media has the potential to undermine immunization programs. Factors associated with improved public confidence in vaccines include evidence-based decision-making procedures and recommendations, controlled processes for licensing and monitoring vaccine safety and effectiveness and disease surveillance. Community engagement with appropriate communication approaches for each audience is a key factor in building trust in vaccines. Vaccine safety/quality issues should be handled rapidly and transparently by informing and involving those most affected and those concerned with public health in effective ways. Openness and transparency in the exchange of information between industry and other stakeholders is also important. To maximize the safety of vaccines, and thus sustain trust in vaccines, partnerships are needed between public health sector stakeholders. Vaccine confidence can be improved through collaborations that ensure high vaccine uptake rates and that inform the public and other stakeholders of the benefits of vaccines and how vaccine safety is constantly assessed, assured and communicated.
References
[1]
Duclos, P.; Okwo-Bele, J.M.; Gacic-Dobo, M.; Cherian, T. Global immunization: Status, progress, challenges and future. BMC Int. Health Hum. Rights 2009, 9, S2, doi:10.1186/1472-698X-9-S1-S2.
[2]
World Health Organization. Global routine vaccination coverage, 2010. Wkly. Epidemiol. Rec. 2011, 86, 509–513.
[3]
Roush, S.W.; Murphy, T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007, 298, 2155–2163, doi:10.1001/jama.298.18.2155.
[4]
State of the World’s Vaccines and Immunization, 3rd ed. ed.; World Health Organization: Geneva, Switzerland, 2009.
[5]
Ozawa, S.; Mirelman, A.; Stack, M.L.; Walker, D.G.; Levine, O.S. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review. Vaccine 2012, 31, 96–108, doi:10.1016/j.vaccine.2012.10.103.
[6]
Stack, M.L.; Ozawa, S.; Bishai, D.M.; Mirelman, A.; Tam, Y.; Niessen, L.; Walker, D.G.; Levine, O.S. Estimated economic benefits during the “decade of vaccines” include treatment savings, gains in labor productivity. Health Aff. (Millwood) 2011, 30, 1021–1028.
[7]
Bonanni, P.; Santos, J. Vaccine Evolution. In Understanding Modern Vaccines: Perspectives in Vaccinology; Gar？on, N., Stern, P.L., Cunningham, A.L., Stanberry, L.R., Eds.; Elsevier B.V.: Amsterdam, the Netherlands, 2011; pp. 1–14.
[8]
Blank, P.R.; Schwenkglenks, M.; Szucs, T.D. Disparities in influenza vaccination coverage rates by target group in five European countries: Trends over seven consecutive seasons. Infection 2009, 37, 390–400, doi:10.1007/s15010-009-8467-y.
[9]
Centers for Disease Control and Prevention. Global routine vaccination coverage, 2010. Morb. Mortal. Wkly. Rep. 2011, 60, 1520–1522.
[10]
World Health Organization. Draft Global Vaccine Action Plan. Report by the Secretariat; World Health Organization: Geneva, Switzerland, 2012.
[11]
Moxon, E.R.; Das, P.; Greenwood, B.; Heymann, D.L.; Horton, R.; Levine, O.S.; Plotkin, S.; Nossal, G. A call to action for the new decade of vaccines. Lancet 2011, 378, 298–302, doi:10.1016/S0140-6736(11)60766-6.
[12]
Bill & Melinda Gates Foundation. Bill and Melinda Gates pledge $10 billion in call for Decade of Vaccines. Increased vaccination could save more than 8 million children by 2020; significant funding gaps remain, others must join effort. Available online: http://www.gatesfoundation.org/ press-releases/Pages/decade-of-vaccines-wec-announcement-100129.aspx (accessed on 23 January 2013).
[13]
Larson, H.J.; Cooper, L.Z.; Eskola, J.; Katz, S.L.; Ratzan, S. Addressing the vaccine confidence gap. Lancet 2011, 378, 526–535.
[14]
Burnett, R.J.; Larson, H.J.; Moloi, M.H.; Tshatsinde, E.A.; Meheus, A.; Paterson, P.; Francois, G. Addressing public questioning and concerns about vaccination in South Africa: A guide for healthcare workers. Vaccine 2012, 30, C72–C78.
[15]
Glanz, J.M.; Newcomer, S.R.; Narwaney, K.J.; Hambidge, S.J.; Daley, M.F.; Wagner, N.M.; McClure, D.L.; Xu, S.; Rowhani-Rahbar, A.; Lee, G.M.; et al. A population-based cohort study of undervaccination in 8 managed care organizations across the United States. JAMA 2013, 1–8.
[16]
Kim, T.H.; Johnstone, J.; Loeb, M. Vaccine herd effect. Scand. J. Infect. Dis. 2011, 43, 683–689.
[17]
World Health Organization. Global Vaccine Safety Blueprint; Quality, Safety and Standards unit of the Department of Immunization, Vaccines and Biologicals: Geneva, Switzerland, 2012.
[18]
Pan American Health Organization. Immunization Safety. How to Address Events Allegedly Attributable to Vaccination or Immunization; PAHO/WHO: Washington, DC, USA, 2002.
[19]
Lantos, J.D.; Jackson, M.A.; Opel, D.J.; Marcuse, E.K.; Myers, A.L.; Connelly, B.L. Controversies in vaccine mandates. Curr. Probl. Pediatr. Adolesc. Health Care 2010, 40, 38–58.
[20]
Stanton, B.F. Assessment of relevant cultural considerations is essential for the success of a vaccine. J. Health Popul. Nutr. 2004, 22, 286–292.
[21]
Lau, C.Y.; Stansbury, J.P.; Gust, D.A.; Kafaar, Z. Social and behavioral science in HIV vaccine trials: A gap assessment of the literature. Expert Rev. Vaccines 2009, 8, 179–190.
[22]
Funk, S.; Salathé, M.; Jansen, V.A. Modelling the influence of human behaviour on the spread of infectious diseases: A review. J. R. Soc. Interface 2010, 7, 1247–1256, doi:10.1098/rsif.2010.0142.
[23]
Myers, L.B.; Goodwin, R. Determinants of adults’ intention to vaccinate against pandemic swine flu. BMC Public Health 2011, 11, 15.
[24]
Connolly, T.; Reb, J. Toward interactive, Internet-based decision aid for vaccination decisions: Better information alone is not enough. Vaccine 2012, 30, 3813–3818.
[25]
MacDonald, N.E.; Smith, J.; Appleton, M. Risk perception, risk management and safety assessment: What can governments do to increase public confidence in their vaccine system? Biologicals 2012, 40, 384–388.
[26]
Muscat, M. Who gets measles in Europe? J. Infect. Dis. 2011, 204, S353–S365.
[27]
Jones, A.M.; Omer, S.B.; Bednarczyk, R.A.; Halsey, N.A.; Moulton, L.H.; Salmon, D.A. Parents’ source of vaccine information and impact on vaccine attitudes, beliefs, and nonmedical exemptions. Adv. Prev. Med. 2012, 2012, 932741.
[28]
Centers for Disease Control and Prevention. Some common misconceptions about vaccination and how to respond to them.
[29]
Betsch, C.; Brewer, N.T.; Brocard, P.; Davies, P.; Gaissmaier, W.; Haase, N.; Leask, J.; Renkewitz, F.; Renner, B.; Reyna, V.F.; et al. Opportunities and challenges of Web 2.0 for vaccination decisions. Vaccine 2012, 30, 3727–3733.
[30]
Betsch, C.; Sachse, K. Dr. Jekyll or Mr. Hyde? (How) the Internet influences vaccination decisions: Recent evidence and tentative guidelines for online vaccine communication. Vaccine 2012, 30, 3723–3726.
[31]
Kata, A. Anti-vaccine activists, Web 2.0, and the postmodern paradigm—An overview of tactics and tropes used online by the anti-vaccination movement. Vaccine 2012, 30, 3778–3789, doi:10.1016/j.vaccine.2011.11.112.
[32]
Poland, G.A.; Jacobson, R.M. The clinician’s guide to the anti-vaccinationists’ galaxy. Hum. Immunol. 2012, 73, 859–866, doi:10.1016/j.humimm.2012.03.014.
[33]
Carrillo-Santisteve, P.; Lopalco, P.L. Measles still spreads in Europe: Who is responsible for the failure to vaccinate? Clin. Microbiol. Infect. 2012, 18, 50–56, doi:10.1111/j.1469-0691.2012.03982.x.
[34]
Muscat, M.; Bang, H.; Glismann, S. Measles is still a cause for concern in Europe. Eur. Surveill. 2008, 13.
[35]
Jegede, A.S. What led to the Nigerian boycott of the polio vaccination campaign? PLoS Med. 2007, 4, e73, doi:10.1371/journal.pmed.0040073.
[36]
Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication—Nigeria, January 2011–September 2012. MMWR Morb. Mortal. Wkly. Rep. 2012, 61, 899–904.
[37]
Taylor, K.; Nguyen, A.; Stéphenne, J. The need for new vaccines. Vaccine 2009, 27, G3–G8, doi:10.1016/j.vaccine.2009.10.014.
[38]
Kennedy, A.; Lavail, K.; Nowak, G.; Basket, M.; Landry, S. Confidence about vaccines in the United States: Understanding parents’ perceptions. Health Aff. (Millwood) 2011, 30, 1151–1159.
Shen, A.K.; Spinner, J.R.; Salmon, D.A.; Gellin, B.G. Strengthening the U.S. vaccine and immunization enterprise: The role of the National Vaccine Advisory Committee. Public Health Rep. 2011, 126, 4–8.
[41]
Duclos, P.; Ortynsky, S.; Abeysinghe, N.; Cakmak, N.; Janusz, C.B.; Jauregui, B.; Mihigo, R.; Mosina, L.; Sadr-Azodi, N.; Takashima, Y.; et al. Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups. Vaccine 2012, 30, 7147–7152, doi:10.1016/j.vaccine.2012.04.015.
[42]
Bridges, C.B.; Woods, L.; Coyne-Beasley, T. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older—United States, 2013. Morb. Mortal. Wkly. Rep. 2013, 62, 9–19.
Marshall, V.; Baylor, N.W. Food and Drug Administration regulation and evaluation of vaccines. Pediatrics 2011, 127, S23–S30, doi:10.1542/peds.2010-1722E.
[45]
Lebron, J.A.; Wolf, J.J.; Kaplanski, C.V.; Ledwith, B.J. Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev. Vaccines 2005, 4, 855–866, doi:10.1586/14760584.4.6.855.
[46]
European Medicines Agency. Guideline on the Conduct of Pharmacovigilance for Vaccines for Pre- and Post-exposure Prophylaxis against Infectious Diseases; European Medicines Agency: London, UK, 2009.
[47]
Leroux-Roels, G.; Bonanni, P.; Tantawichien, T.; Zepp, F. Vaccine Development. In Understanding Modern Vaccines: Perspectives in Vaccinology; Gar？on, N., Stern, P.L., Cunningham, A.L., Stanberry, L.R., Eds.; Elsevier B.V.: Amsterdam, The Netherlands, 2011; pp. 115–150.
[48]
Bonhoeffer, J.; Black, S.; Izurieta, H.; Zuber, P.; Sturkenboom, M. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe. Biologicals 2012, 40, 393–397, doi:10.1016/j.biologicals.2012.07.007.
[49]
World Health Organization. Vaccine Introduction Guidelines. Adding a Vaccine to a National Immunization Program: Decision and Implementation; World Health Organization: Geneva, Switzerland, 2005.
[50]
The National Vaccine Advisory Committee. A report of the National Vaccine Advisory Committee. Strengthening the supply of routinely recommended vaccines in the United States.
[51]
Strugnell, R.; Zepp, F.; Cunningham, A.L.; Tantawichien, T. Vaccine Antigens. In Understanding Modern Vaccines: Perspectives in Vaccinology; Gar？on, N., Stern, P.L., Cunningham, A.L., Stanberry, L.R., Eds.; Elsevier B.V.: Amsterdam, The Netherlands, 2011; pp. 61–88.
[52]
Minor, P. Considerations for setting the specifications of vaccines. Expert Rev. Vaccines 2012, 11, 579–585, doi:10.1586/erv.12.23.
[53]
Dellepiane, N.; Griffiths, E.; Milstien, J.B. New challenges in assuring vaccine quality. Bull. World Health Organ. 2000, 78, 155–162.
[54]
Wilkie, D. The Chiron case: Good Manufacturing Practice gone bad. Available online: http://www.the-scientist.com/?articles.view/articleNo/16290/title/The-Chiron-Case--Good-Manufacturing-Practice-Gone-Bad/ (accessed on 23 January 2013).
[55]
MacDonald, G. GSK pulls vaccine batch in Canada over contamination concerns. Available online: http://www.in-pharmatechnologist.com/Regulatory-Safety/GSK-pulls-vaccine-batch-in-Canada-over-contamination-concerns/ (accessed on 23 January 2013).
[56]
Taylor, N. India plans $37m investment in vaccine cGMP compliance. Available online: http://www.in-pharmatechnologist.com/Processing/India-plans-37m-investment-in-vaccine-cGMP-compliance/ (accessed on 3 January 2013).
[57]
Centers for Disease Control and Prevention. Recalled vaccines.
[58]
World Health Organization. The Global Vaccine Safety Initiative (GVSI).
[59]
ICH. ICH Harmonised Tripartite Guideline; ICH: Geneva, Switzerland, 2004. Available online: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf (accessed on 30 May 2013).
[60]
European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP). Module VII—Periodic Safety Update Report; European Medicines Agency: London, UK, 2012.
European Medicines Agency. EudraVigilance. Available online: http://eudravigilance.ema. europa.eu/human/index.asp (accessed on 3 December 2012).
[63]
Lieu, T.A.; Kulldorff, M.; Davis, R.L.; Lewis, E.M.; Weintraub, E.; Yih, K.; Yin, R.; Brown, J.S.; Platt, R. Real-time vaccine safety surveillance for the early detection of adverse events. Med. Care 2007, 45, S89–S95, doi:10.1097/MLR.0b013e3180616c0a.
[64]
Baggs, J.; Gee, J.; Lewis, E.; Fowler, G.; Benson, P.; Lieu, T.; Naleway, A.; Klein, N.P.; Baxter, R.; Belongia, E.; et al. The Vaccine Safety Datalink: A model for monitoring immunization safety. Pediatrics 2011, 127, S45–S53, doi:10.1542/peds.2010-1722H.
[65]
Eurosurveillance Editorial Team. ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Euro Surveill. 2009, 14, 19345.
[66]
Laverty, H.; Gunn, M.; Goldman, M. Improving R&D productivity of pharmaceutical companies through public-private partnership: Experiences from the Innovative Medicines Initiative. Expert Rev. Pharmacoecon. Outcomes Res. 2012, 12, 545–548, doi:10.1586/erp.12.59.
[67]
World Health Organization. Global Advisory Committee on Vaccine Safety, 3–4 December 2009. Wkly. Epidemiol. Rec. 2010, 85, 29–33.
[68]
Graham, J.E.; Borda-Rodriguez, A.; Huzair, F.; Zinck, E. Capacity for a global vaccine safety system: The perspective of national regulatory authorities. Vaccine 2012, 30, 4953–4959, doi:10.1016/j.vaccine.2012.05.045.
[69]
Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine—United States, 1998–1999. Morb. Mortal. Wkly. Rep. 1999, 48, 577–581.
[70]
Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. Morb. Mortal. Wkly. Rep. 1999, 48, 1007.
[71]
Velázquez, F.R.; Colindres, R.E.; Grajales, C.; Hernández, M.T.; Mercadillo, M.G.; Torres, F.J.; Cervantes-Apolinar, M.; DeAntonio-Suarez, R.; Ortega-Barria, E.; Blum, M.; et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr. Infect. Dis. J. 2012, 31, 736–744, doi:10.1097/INF.0b013e318253add3.
[72]
Shui, I.M.; Baggs, J.; Patel, M.; Parashar, U.D.; Rett, M.; Belongia, E.A.; Hambidge, S.J.; Glanz, J.M.; Klein, N.P.; Weintraub, E. Risk of intussusception following administration of a pentavalent rotavirus vaccine in U.S. infants. JAMA 2012, 307, 598–604, doi:10.1001/jama.2012.97.
[73]
Buttery, J.P.; Danchin, M.H.; Lee, K.J.; Carlin, J.B.; McIntyre, P.B.; Elliott, E.J.; Booy, R.; Bines, J.E. Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011, 29, 3061–3066, doi:10.1016/j.vaccine.2011.01.088.
[74]
Patel, M.M.; López-Collada, V.R.; Bulh？es, M.M.; de Oliveira, L.H.; Bautista Márquez, A.; Flannery, B.; Esparza-Aguilar, M.; Montenegro Renoiner, E.I.; Luna-Cruz, M.E.; Sato, H.K.; et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N. Engl. J. Med. 2011, 364, 2283–2292, doi:10.1056/NEJMoa1012952.
[75]
Loughlin, J.; Mast, T.C.; Doherty, M.C.; Wang, F.T.; Wong, J.; Seeger, J.D. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr. Infect. Dis. J. 2012, 31, 292–296, doi:10.1097/INF.0b013e3182421390.
[76]
World Health Organization. Rotavirus vaccines. WHO position paper—January 2013. Wkly. Epidemiol. Rec. 2013, 88, 49–64.
[77]
Centers for Disease Control and Prevention. Progress in the introduction of rotavirus vaccine—Latin America and the Caribbean, 2006–2010. Morb. Mortal. Wkly. Rep. 2011, 60, 1611–1614.
[78]
Tate, J.E.; Patel, M.M.; Cortese, M.M.; Lopman, B.A.; Gentsch, J.R.; Fleming, J.; Steele, A.D.; Parashar, U.D. Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality. Expert Rev. Vaccines 2012, 11, 211–220, doi:10.1586/erv.11.184.
[79]
Gasta？aduy, P.A.; Sánchez-Uribe, E.; Esparza-Aguilar, M.; Desai, R.; Parashar, U.D.; Patel, M.; Richardson, V. Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico. Pediatrics 2013, 131, e1115–e1120, doi:10.1542/peds.2012-2797.
[80]
World Health Organization. Immunization surveillance, assessment and monitoring. WHO/UNICEF joint reporting process. Available online: http://www.who.int/immunization_monitoring/routine/joint_reporting/en/index.html#/ (accessed on 28 Janyary 2013).
[81]
World Health Organization. WHO-recommended Standards for Surveillance of Selected Vaccine-preventable Diseases; World Health Organization: Geneva, Switzerland, 2003.
[82]
VENICE II Consortium. Vaccination coverage assessment in EU/EEA, 2011. Available online: http://venice.cineca.org/Final_Vaccination_Coverage_Assesment_Survey_2011_1.pdf (accessed on 23 January 2013).
[83]
Bonanni, P.; Levi, M.; Latham, N.B.; Bechini, A.; Tiscione, E.; Lai, P.; Panatto, D.; Gasparini, R.; Boccalini, S. An overview on the implementation of HPV vaccination in Europe. Hum. Vaccin. 2011, 7, S128–S135, doi:10.4161/hv.7.0.14575.
[84]
World Health Organization. Human papillomavirus vaccines. WHO position paper. Wkly. Epidemiol. Rec. 2009, 84, 118–131.
[85]
Noakes, K.; Yarwood, J.; Salisbury, D. Parental response to the introduction of a vaccine against human papilloma virus. Hum. Vaccin. 2006, 2, 243–248, doi:10.4161/hv.2.6.3391.
[86]
Markowitz, L.E.; Tsu, V.; Deeks, S.L.; Cubie, H.; Wang, S.A.; Vicari, A.S.; Brotherton, J.M. Human papillomavirus vaccine introduction—The first five years. Vaccine 2012, 30, F139–F148, doi:10.1016/j.vaccine.2012.05.039.
[87]
Kane, M.A.; Serrano, B.; de Sanjose, S.; Wittet, S. Implementation of human papillomavirus immunization in the developing world. Vaccine 2012, 30, F192–F200, doi:10.1016/j.vaccine.2012.06.075.
[88]
Watson-Jones, D.; Tomlin, K.; Remes, P.; Baisley, K.; Ponsiano, R.; Soteli, S.; de Sanjose, S.; Changalucha, J.; Kapiga, S.; Hayes, R.J. Reasons for receiving or not receiving HPV vaccination in primary schoolgirls in Tanzania: A case control study. PLoS One 2012, 7, e45231, doi:10.1371/journal.pone.0045231.
[89]
Leask, J.; Kinnersley, P.; Jackson, C.; Cheater, F.; Bedford, H.; Rowles, G. Communicating with parents about vaccination: A framework for health professionals. BMC Pediatr. 2012, 12, 154, doi:10.1186/1471-2431-12-154.
[90]
Simone, B.; Carrillo-Santisteve, P.; Lopalco, P.L. Healthcare workers role in keeping MMR vaccination uptake high in Europe: A review of evidence. Euro Surveill. 2012, 17, 20206.
[91]
Steben, M.; Jeronimo, J.; Wittet, S.; Lamontagne, D.S.; Ogilvie, G.; Jensen, C.; Smith, J.; Franceschi, S. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries. Vaccine 2012, 30, F183–F191, doi:10.1016/j.vaccine.2012.06.031.
[92]
Centers for Disease Control and Prevention. MMR Vaccine. What You Need to Know.
[93]
Centers for Disease Control and Prevention. Measles; Mumps; Rubella. In Epidemiology and Prevention of Vaccine-preventable Diseases, 12th ed. ed.; Public Health Foundation: Washington DC, USA, 2012; pp. 173–192, 205–214, 275–290.
[94]
World Health Organization. 3rd Global meeting on implementing new and under-utilized vaccines, 16–18 June 2009. Workgroup 8. Training of health staff and review of the Global Immunization Training Framework. Available online: http://www.who.int/nuvi/2009_meeting_ summary_training/en/ (accessed on 22 February 2013).
[95]
Wakefield, A.J.; Murch, S.H.; Anthony, A.; Linnell, J.; Casson, D.M.; Malik, M.; Berelowitz, M.; Dhillon, A.P.; Thomson, M.A.; Harvey, P.; et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998, 351, 637–641, doi:10.1016/S0140-6736(97)11096-0.
[96]
Hall, A.; Kane, M.; Roure, C.; Meheus, A. Multiple sclerosis and hepatitis B vaccine? Vaccine 1999, 17, 2473–2475.
[97]
Gangarosa, E.J.; Galazka, A.M.; Wolfe, C.R.; Phillips, L.M.; Gangarosa, R.E.; Miller, E.; Chen, R.T. Impact of anti-vaccine movements on pertussis control: The untold story. Lancet 1998, 351, 356–361, doi:10.1016/S0140-6736(97)04334-1.
[98]
Ascherio, A.; Zhang, S.; Hernan, M.; Olek, M.; Coplan, P.; Brodovicz, K. Hepatitis B vaccination and the risk of multiple sclerosis: Case-control studies. Gastroenterol. Clin. Biol. 2001, 25, 927–929.
[99]
Baleta, A.F.; van den Heever, J.; Burnett, R.J. Meeting the need for advocacy, social mobilisation and communication in the introduction of three new vaccines in South Africa—Successes and challenges. Vaccine 2012, 30, C66–C71, doi:10.1016/j.vaccine.2012.06.033.
[100]
World Health Organization. Communication for Behavioural Impact (COMBI). A Toolkit for Behavioural and Social Communication in Outbreak Response; World Health Organization: Geneva, Switzerland, 2012.
[101]
Wallace, C.; Leask, J.; Trevena, L.J. Effects of a web based decision aid on parental attitudes to MMR vaccination: A before and after study. BMJ 2006, 332, 146–149, doi:10.1136/bmj.38678.681840.68.
[102]
London School of Hygiene & Tropical Medicine. The Vaccine Confidence Project. About the VCI. Available online: http://www.vaccineconfidence.org/VCI.html/ (accessed on 24 January 2013).
[103]
Osterhaus, A.D.; Vanlangendonck, C. About courageous scientists, responsible policy makers, bridge-builders and preparedness for the next influenza pandemic. Vaccine 2012, 30, 7437–7438, doi:10.1016/j.vaccine.2012.09.073.
[104]
Lexchin, J.; Bero, L.A.; Djulbegovic, B.; Clark, O. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 2003, 326, 1167–1170, doi:10.1136/bmj.326.7400.1167.
[105]
Smith, R. Medical journals and pharmaceutical companies: Uneasy bedfellows. BMJ 2003, 326, 1202–1205, doi:10.1136/bmj.326.7400.1202.
[106]
Melander, H.; Ahlqvist-Rastad, J.; Meijer, G.; Beermann, B. Evidence b(i)ased medicine—Selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ 2003, 326, 1171–1173, doi:10.1136/bmj.326.7400.1171.
[107]
Godlee, F. Doctors, patients, and the drug industry. BMJ 2009, 338, b463, doi:10.1136/bmj.b463.
[108]
Lundh, A.; Sismondo, S.; Lexchin, J.; Busuioc, O.A.; Bero, L. Industry sponsorship and research outcome. Cochrane Database Syst. Rev. 2012, 12, MR000033.
[109]
Herxheimer, A. Relationships between the pharmaceutical industry and patients’ organisations. BMJ 2003, 326, 1208–1210, doi:10.1136/bmj.326.7400.1208.
[110]
Abbasi, K.; Smith, R. No more free lunches. BMJ 2003, 326, 1155–1156, doi:10.1136/bmj.326.7400.1155.
[111]
Moynihan, R. Is the relationship between pharma and medical education on the rocks? BMJ 2008, 337, a925, doi:10.1136/bmj.a925.
[112]
Moynihan, R. Key opinion leaders: Independent experts or drug representatives in disguise? BMJ 2008, 336, 1402–1403.
[113]
Coombes, R. Drug industry’s new code criticised for lacking teeth. BMJ 2005, 331, 1225, doi:10.1136/bmj.331.7527.1225-a.
[114]
Maeda, Y.; Miyahara, M. Determinants of trust in industry, government, and citizen’s groups in Japan. Risk Anal. 2003, 23, 303–310, doi:10.1111/1539-6924.00310.
[115]
DeAngelis, C.D.; Drazen, J.M.; Frizelle, F.A.; Haug, C.; Hoey, J.; Horton, R.; Kotzin, S.; Laine, C.; Marusic, A.; Overbeke, A.J.; et al. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. JAMA 2004, 292, 1363–1364, doi:10.1001/jama.292.11.1363.
[116]
ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
[117]
Godlee, F.; Groves, T. The new BMJ policy on sharing data from drug and device trials. BMJ 2012, 345, e7888, doi:10.1136/bmj.e7888.
